Having been tested by our leading experts, we’re proud to be the first to introduce Stockholm3 to the UK. While there is currently no national screening programme for the disease in Britain, Stockholm3 is a pioneering blood-based diagnostic test that helps predict the risk of prostate cancer in men aged 45-74 with no previous diagnosis, using a combination of protein and genetic biomarkers, along with clinical data and a cutting-edge algorithm. Find out more.